

Introduction & Notes re: MVB Annual Assessment Setting Workbook

MVB Calendar Year 2022

[Note: This is Working Version as of 10/25/2021.]

01. This workbook follows the past naming conventions with each sheet beginning with a letter (i.e., "a." through "d."), and each cell within each sheet being identified by a 2-digit row number (e.g., "01.") and column letter (e.g., "A"). So, to facilitate reference while collaborating via conference phone, users can refer to any single number, for example the new assessment rate, by a combination of the above. For that key number, the new monthly assessment rate, the reference is "a.26.C".
02. Since the first measurement period is for the month of January and assessments are due forty-five (45) days after the end of each quarter, the first assessment payment with the new rate will be May 15, 2022 for the months of Jan-Mar, 2022.
03. The primary spreadsheet for the work is the assessment calculation worksheet, worksheet a. The other sheets are intended to be reference or to develop background data in specific areas for the work. Key data for developing the primary funding target is on spreadsheet b. which contains data supplied by the Maine CDC for the vaccine funding needs. Key numbers from a subsidiary sheet rolled into the main assessment sheet generally are shaded in yellow.
04. These spreadsheets have Board controls. This is intended to help users test various assumptions and control points which may be adjusted by the MVB in setting the final new rate. Those cells in which entries normally would be made are shaded in green. For example, a user can adjust utilization assumptions for increases over prior years by entering percent's either by vaccine on sheet b. or overall on sheet a (a.3.D). The vaccine funding target takes the number as adjusted by those two factors and then applies the assumed cost increase (a.4.D). The cost increase is applied for 9/12 of the year since it typically becomes effective as of April 1 each year.
05. Because the first collections of the year (due February 15) will still be at the old rate and based upon covered lives reported for Oct-Dec 2021, this spreadsheet first deducts that quarterly collection and then calculates the new rate based upon what is needed to hit the funding target over the remaining 9 months.
06. It is anticipated that the MVB will, as part of its deliberations and upon considering the input of any public members or others at its meeting(s), adjust the assumptions which guide the assessment level. Of course, the MVB may also determine to adjust the assessment setting process itself or this workbook structure at any time.

Maine Vaccine Board

2022 Calendar Year Assessment Calculation

Column →	A	B	C	D	E
Line ↓	2021		2022		
A. Preliminary Vaccine Cost, Projection Parameters, & Population Estimates					
01.	\$14,258,134		\$15,140,087		State Fiscal Year Vaccine Estimate (from tab b.)
02.	139,371		136,487		Estimate of Covered Lives (Covered Lives tab c.)
03.	\$142,581	1.0%	\$151,401	1.0%	Provision for Vaccine Utilization increase
04.	\$486,024	4.5%	\$470,213	4.1%	Vaccine cost inflation factor (prices change each April 1st)
05.	\$14,886,740		\$15,761,701		¹ Calendar Year Vaccine Funding Estimate
B. Budget Estimates					
06.	\$152,021		\$153,351		³ Servicing Agent Contract for Administrative Services
07.	\$7,000		\$7,350		Audit Fee (Move to paid public auditor)
08.	\$7,252		\$7,500		Bank Fees (adding TD Bank Lockbox including setup expenses)
09.	\$10,500		\$10,500		Legal (services of AG's office only estimated)
10.	\$176,773		\$178,701		Total Operating Costs Projected
C. Financial Carry Forwards					
11.	\$6,582,936		\$5,940,967		Estimated Starting Balance January 1
12.	\$3,508,078	3.0	\$3,800,499	3.0%	Amount Retained for Liquidity Reserve - 3.0 months of non flu
13.	\$854,426		\$559,704		Amount Retained for Liquidity Reserve - full annual flu cost
14.	\$2,220,431		\$1,580,764		Carryforward used to reduce current assessment calculation
D. Aggregate Annual Assessment Calculation					
15.	\$14,886,740		\$15,761,701		Costs of Vaccines Provided
16.	\$176,773		\$178,701		Total Operating Costs
17.	\$0		\$0		Other (as approved by board -- see statute section 2.M)
18.	\$15,063,513		\$15,940,402		"Total Costs of the Fund" per statute section 2.M.
19.	\$52,722	0.35%	\$55,791	0.35%	Collection Losses (i.e. assumed "bad debt expense")
20.	-\$113,253		-\$102,607		² Interest Income
21.	-\$2,220,431	-14.7%	-\$1,580,764	-9.9%	(excess) or shortfall of cash from prior operating year
22.	\$527,223	3.50%	\$557,914	3.50%	add reserve up to 10% per statute section 5.A.(3).
23.	\$13,309,774		\$14,870,737		Total Assessments Needed
24.	-\$3,326,463		-\$3,258,905		Projected assessments February 15 at old rate
25.	\$9,983,311		\$11,611,832		Total Assessments Needed at new rate
E. Per Covered Life Assessment Calculation					
26.	\$95.51		\$113.44		Annual Assessment per Covered Life
27.	\$7.96		\$9.45		Monthly Assessment per Covered Life
28.	4.6%		6.2%		% Change in Vaccine Costs
29.	0.04%		18.8%		% Change in Assessment
F. Note: Total Assessed as % of Hard Vaccine Costs					
30.	-10.59%		-5.7%		All-in costs % above vaccine costs
G. Indicated Monthly Assessment Level next year apart from reserve / cash changes					
31.	\$9.99		\$10.48		⁴ Preliminary Assessment projection

Notes

- ¹ Maine CDC + per vaccine adjustments + utilization increase with inflation factor.
- ² Used the average of FY17-FY21 excluding FY19 (TRICARE payment made it outlier) Investment Income from audited financials.
- ³ Fixed price contract all inclusive of expenses.
- ⁴ Projection: annual amounts w/ carryforward cash, reserve changes, and 1 more year of inflation & utilization changes.

Maine CDC Vaccine Projection Data

Column →

A B C D E F G H I J K

Line ↓

Line	Vaccine	Brand Name	NDC	Prior Year Actuals			Federal FY 22 Estimates			Vaccine Funding Target	
				Cost Per Dose	Doses	Cost	Cost Per Dose	Doses	Cost		
01.	DAPTACEL	Sanofi Pastuer	49281-0286-10	\$ 18.55	3,750	\$ 69,548	\$ 19.20	6,168	\$118,438	0%	\$118,438
1.b				\$ 19.20	952	\$ 18,280.30					
02.	PENTACEL	Sanofi Pastuer	49281-0511-05	\$ 61.65	8,941	\$ 551,194.77	\$ 63.38	8,243	\$522,474	0%	\$522,474
2.b				\$ 63.38	1,793	\$ 113,647.51					
03.	QUADRACEL	Sanofi Pastuer	49281-0562-10	\$ 41.80	1,338	\$ 55,924.39	\$ 43.35	1,968	\$85,317	0%	\$85,317
3.b				\$ 43.35	287	\$ 12,442.02					
04.	IPOL (EIPV)	Sanofi Pastuer	49281-0860-10	\$ 13.85	2,531	\$ 35,054.35	\$ 14.06	2,771	\$38,960	0%	\$38,960
4.b				\$ 14.06	660	\$ 9,279.60					
05.	Menactra (MCV4)	Sanofi Pastuer	49281-0589-05	\$ 96.23	10,063	\$ 968,382.62	\$ 100.05	14,305	\$1,431,215	0%	\$1,431,215
5.b				\$ 100.05	1,547	\$ 154,777.35					
06.	Medquadfi	Sanofi Pastuer	49281-0590-05	\$ -	0	\$ -	\$ 100.05	831	\$83,142	0%	\$83,142
	ACTHIB (HIB)	Sanofi Pastuer	49281-0545-03	\$ 9.75	4,272	\$ 41,634.91	\$ 10.02	5,369	\$53,797	0%	\$53,797
07.				\$ 10.02	919	\$ 9,208.38					
7.b	ADACEL (Tdap)	Sanofi Pastuer	49281-0400-10	\$ 32.63	343	\$ 11,193.46	\$33.16	2,640	\$87,542	0%	\$87,542
08.			49281-0400-20	\$ 32.63	1,158	\$ 37,790.17					
8.b				\$ 33.16	818	\$ 27,124.88					
09.	TENIVAC	Sanofi Pastuer	49281-0215-15	\$ 21.18	148	\$ 3,134.64	\$21.77	100	\$2,177	0%	\$2,177
9.b				\$ 21.77	42	\$ 914.34					
10.	TRUMENBA (Menb)	Pfizer	00005-0100-10	\$ 114.36	176	\$ 20,127.36	\$119.93	300	\$35,979	0%	\$35,979
10.b				\$ 119.93	33	\$ 3,957.69					
11.	Prevnar 13 (PCV 13)	Pfizer	00005-1971-02	\$ 143.82	17,605	\$ 2,531,951.10	\$150.83	20,884	\$3,149,934	0%	\$3,149,934
11.b				\$ 150.83	3,444	\$ 519,459					
11.c	Bexsero (Menb)	GlaxoSmithKline	58160-0976-06	\$ 120.24	2,226	\$ 267,654	\$128.60	2,705	\$347,874	0%	\$347,874
12.				\$ 128.60	424	\$ 54,528					
12.b	MENVEO (MCV4)	GlaxoSmithKline	58160-0955-09	\$ 95.78	2,222	\$ 212,823	\$99.58	3,635	\$361,981	0%	\$361,981
12.c				\$ 99.58	390	\$ 38,836					
13.	Infanrix (DTaP)	GlaxoSmithKline	58160-0810-52	\$ 19.16	819	\$ 15,694	\$19.84	1,237	\$24,542	0%	\$24,542
13.b				\$ 19.84	237	\$ 4,702					
13.c	Pediarix (DTaP/Hep B/IPV)	GlaxoSmithKline	58160-0811-52	\$ 60.71	5,100	\$ 309,616	\$62.49	4,468	\$279,214	0%	\$279,214
14.				\$ 62.49	1,093	\$ 68,303					
14.b	Kinrix (DTaP/IPV)	GlaxoSmithKline	58160-0812-52	\$ 42.46	4,246	\$ 180,281	\$43.64	6,271	\$273,685	0%	\$273,685
15.				\$ 43.64	649	\$ 28,324					
15.b	Havrix (Hep A)	GlaxoSmithKline	58160-0825-52	\$ 21.11	10,559	\$ 222,932	\$21.72	14,335	\$311,414	0%	\$311,414
15.c				\$ 21.72	1,997	\$ 43,381					
16.	Engerix-B (Hep B)	GlaxoSmithKline	58160-0820-52	\$ 15.38	4,162	\$ 64,012	\$15.67	3,780	\$59,244	0%	\$59,244
16.b				\$ 15.67	808	\$ 12,663					
16.c	Rotarix (Rota)	GlaxoSmithKline	58160-0854-52	\$ 97.51	3,031	\$ 295,547	\$99.44	3,835	\$381,364	0%	\$381,364
17.				\$ 99.44	605	\$ 60,163					
17.b	Boostrix (TDaP)	GlaxoSmithKline	58160-0842-52	\$ 33.14	5,667	\$ 187,804	\$34.07	7,099	\$241,842	0%	\$241,842

Maine CDC Vaccine Projection Data

18.			\$ 34.07	1,112	\$ 37,886							
18.b	HIBERIX	GlaxoSmithKline	58160-0818-11	\$ -	0	\$ -	\$9.62	500	\$4,811	0%	\$4,811	
19.	VAQTA (Hep A)	Merck Sharp & Dohme Corp.	00006-4095-02	\$ 20.61	2,087	\$ 43,013	\$21.40	3,847	\$82,326	0%	\$82,326	
19.b				\$ 21.40	568	\$ 12,155						
19.c	RECOMBIVAX (Hep B)	Merck Sharp & Dohme Corp.	00006-4981-00	\$ 12.53	2,337	\$ 29,283	\$13.00	4,795	\$62,335	0%	\$62,335	
20.				\$ 13.00	788	\$ 10,244						
20.b	PedvaxHib (Hib)	Merck Sharp & Dohme Corp.	00006-4897-00	\$ 13.51	3,780	\$ 51,083	\$13.79	5,211	\$71,860	0%	\$71,860	
21.				\$ 13.79	1,015	\$ 13,997						
21.b	Gardasil (HPV9)	Merck Sharp & Dohme Corp.	00006-4121-02	\$ 187.01	11,770	\$ 2,201,108	\$196.32	18,435	\$3,619,159	0%	\$3,619,159	
22.				\$ 196.32	2,081	\$ 408,542						
22.b	Vaxelis	Merck Sharp & Dohme Corp.	63361-0243-15	\$ -	0	\$ -	\$91.59	4,568	\$418,383	0%	\$418,383	
23.				\$ -	0	\$ -						
23.b	ROTATEQ (Rota)	Merck Sharp & Dohme Corp.	00006-4047-41	\$ 71.88	7,534	\$ 541,544	\$74.73	8,600	\$642,678	0%	\$642,678	
24.				\$ 74.73	1,341	\$ 100,213						
24.b	MMR II	Merck Sharp & Dohme Corp.	00006-4681-00	\$ 21.71	5,656	\$ 122,780	\$22.11	7,075	\$156,428	0%	\$156,428	
24.c				\$ 22.11	1,203	\$ 26,598						
24.d	Proquad (MMRV)	Merck Sharp & Dohme Corp.	00006-4171-00	\$ 137.52	1,970	\$ 270,907	\$144.63	6,462	\$934,567	0%	\$934,567	
25.				\$ 144.63	1,000	\$ 144,625						
26.	Pneumovax23 (Pedi)	Merck Sharp & Dohme Corp.	00006-4837-03	\$ 59.12	58	\$ 3,429	\$62.08	100	\$6,208	0%	\$6,208	
26.b				\$ 62.08	36	\$ 2,235						
27.	Varivax	Merck Sharp & Dohme Corp.	00006-4827-00	\$ 109.26	1,990	\$ 217,427	\$115.77	5,973	\$691,494	0%	\$691,494	
27.b				\$ 115.77	555	\$ 64,252						
28.	Fluzone PF 0.5ml (6mth+)	Sanofi Pasteur	49281-0421-50	\$ 13.76	34,000	\$ 467,670	\$13.76	34,000	\$467,840	0%	\$467,840	
28.b	FluMist Sprayer, 10-pack (2-18)	Astra Zeneca	66019-0308-10	\$ 18.88	4,500	\$ 84,960	\$18.88	4,500	\$84,960	0%	\$84,960	
29.	Flulaval PF 0.5ml (6mth+)	GlaxoSmithKline	19515-0818-52	\$ 14.25	34,000	\$ 484,500	\$14.25	485	\$6,904	0%	\$6,904	
29.b				\$ -	0	\$ -						
30.				\$ -	0	\$ -						
31.				\$ -		\$ -						
32.				\$ -	0	\$ -						
33.				\$ -	0	\$ -						
34.						\$ 12,600,740			\$15,140,087	\$69.26	\$15,140,087	
35.	TOTAL			224,436		\$ 12,600,740		215,495	\$15,140,087		\$15,140,087	
36.											Adjusted for overall utilization increase	\$15,291,488
37.											Adjusted for price increase	\$15,761,701

Maine Vaccine Board
Estimated Covered Lives
2022 Calendar Year Assessment Calculation

Covered lives reported to KV for historical quarters:

	<u>Quarter</u>	<u>Monthly Average</u>	<u>Quarterly Change</u>	<u>12 Month Average</u>	
				<u>Lives</u>	<u>R12 Trend</u>
Q1 ending 9/30/2018	416,686	138,895	-0.85%	138,319	1.99%
Q2 ending 12/31/2018	417,763	139,254	0.26%	138,881	2.14%
Q3 ending 3/31/2019	422,914	140,971	1.23%	139,802	2.63%
Q4 ending 6/30/2019	419,499	139,833	-0.81%	139,739	1.70%
Q1 ending 9/30/2019	416,061	138,687	-0.82%	139,686	0.99%
Q2 ending 12/31/2019	415,098	138,366	-0.23%	139,464	0.42%
Q3 ending 3/31/2020	421,684	140,561	1.59%	139,362	-0.31%
Q4 ending 6/30/2020	419,608	139,869	-0.49%	139,371	-0.26%
Q1 ending 9/30/2020	409,412	136,471	-2.43%	138,817	-0.62%
Q2 ending 12/31/2020	410,327	136,776	0.22%	138,419	-0.75%
Q3 ending 3/31/2021	411,052	137,017	0.18%	137,533	-1.31%
Q4 ending 6/30/2021	407,050	135,683	-0.97%	136,487	-2.07%
Best Current Estimate				136,487	

Liquidity and Reserve Calculations

Column →	A	B	C
Line ↓			
Starting Balances			
01.	Cash Balance as of	28-Sep-2021	\$7,534,842
02.			
03.			
04.			\$7,534,842
Estimated Revenues			
05.	Final Quarterly Assessment (same as most recent collection)		\$3,215,752
06.			
07.			
08.			
09.			\$3,215,752
Expenditures / Allowances			
10.	¹ 1/4 of Annual Vaccine Cost Estimate		\$3,645,096
11.	¹ 1/4 of Annual Operating Budget Estimate		\$44,193
12.	Accounts Payables in Process per Maine CDC		\$538,445
13.	Pending Journal transfer per Maine CDC		\$581,893
14.			
15.			
16.			
17.			
18.	Total Expenditures		\$4,809,627
19.	Estimated Starting Balance January 1		\$5,940,967
20.	Target Months Cash (Non-Flu)	3.0	\$3,800,499
21.	Target Cash for Flu		\$559,704
22.	Target Cash Reserve (Line 20 + Line 21)		\$4,360,203
23.	Excess Cash Balance Above Cash target		\$1,580,764

Notes:

¹ This is 1/4 because September bills have been paid or are pending and accounted for.

**Maine Vaccine Board
Vaccine Assessment Change Walk Down**

Column → Line ↓	A	B	C	D	E	F	G
2022 Calendar Year Assessment Calculation							
	<u>Prior Year</u>	<u>2022</u>	<u>Change from Prior Year</u>			<u>Walk</u>	
			<u>Aggregate \$</u>	<u>Distribution</u>	<u>Per Enrollee</u>	<u>Down</u>	
01. Estimated vaccine costs	\$14,886,740	\$15,761,701	\$874,962	53.7%	\$0.71	8.9%	
02. Total operational costs	\$176,773	\$178,701	\$1,928	0.1%	\$0.00	0.0%	
03. Bad debt and investment income	-\$60,531	-\$46,815	\$13,715	0.8%	\$0.01	0.1%	
04. Net working capital reserve/carry forward	-\$1,693,208	-\$1,022,850	\$670,358	41.2%	\$0.55	6.9%	
05. Projected assessment at old rate	<u>-\$3,326,463</u>	<u>-\$3,258,905</u>	<u>\$67,558</u>	<u>4.1%</u>	<u>\$0.05</u>	<u>0.7%</u>	
06. Total	\$9,983,311	\$11,611,832	\$1,628,521	100.0%	\$1.33	16.7%	
07. Covered Lives	139,371	136,487	-2,884			2.1%	
08. Total						18.8%	
09. Assessment	\$7.96	\$9.45			\$1.49	18.8%	